2008
DOI: 10.1152/ajpheart.01357.2007
|View full text |Cite
|
Sign up to set email alerts
|

An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes

Abstract: This study determined the role of a slowly inactivating component of sodium current (I(Na)), late I(Na), to induce delayed afterdepolarizations (DADs) and triggered activity. We hypothesized that an increase of late I(Na) may induce not only early afterdepolarizations (EADs), but also intracellular calcium overload and DADs. Guinea pig atrial myocytes were studied using the whole cell patch-clamp technique. Anemone toxin II (ATX-II) (5-10 nmol/l) was used to enhance late I(Na). Ranolazine (10 micromol/l) and T… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

5
152
0
5

Year Published

2009
2009
2016
2016

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 139 publications
(163 citation statements)
references
References 50 publications
5
152
0
5
Order By: Relevance
“…Enhanced I Na-Late leads to intracellular Na + loading, which elevates intracellular Ca 2+ through the Na + /Ca 2+ exchanger, inducing a Ca 2+ -dependent transient inward current and triggering activity (16,20,27). However, to the best of our knowledge, the impact of the I Na-Late on SANs has not yet been studied.…”
Section: Discussionmentioning
confidence: 99%
“…Enhanced I Na-Late leads to intracellular Na + loading, which elevates intracellular Ca 2+ through the Na + /Ca 2+ exchanger, inducing a Ca 2+ -dependent transient inward current and triggering activity (16,20,27). However, to the best of our knowledge, the impact of the I Na-Late on SANs has not yet been studied.…”
Section: Discussionmentioning
confidence: 99%
“…Therefore inhibition of I Na.L is considered to be a new potential therapeutic target for treat patients afflicted with heart failure or ischemic heart disease (18,20,21). Approved by the US Food and Drug Administration (FDA) as an antianginal drug in 2006 (11,22), ranolazine (RAN) was first applied as an inhibitor of I Na.L in clinical treatment (12,23). Experimentally, RAN can relieve intracellular Na + and Ca 2+ overload caused by myocardial ischemia via blocking I Na.L (21, 24 -27).…”
Section: Introductionmentioning
confidence: 99%
“…[50][51][52] If a DAD reaches threshold for an AP to occur, triggered activity and extrasystolic activity follow. 51,53 Pharmacological enhancement of I Na,late has been shown to induce DADs and triggered activity. 48,53 Furthermore, inhibition of I Na,late by ranolazine reduces the incidence of DADs and prevents triggered activity.…”
mentioning
confidence: 99%
“…51,53 Pharmacological enhancement of I Na,late has been shown to induce DADs and triggered activity. 48,53 Furthermore, inhibition of I Na,late by ranolazine reduces the incidence of DADs and prevents triggered activity. 16,48,[53][54][55] Delayed afterdepolarizations have been observed in several types of cardiac tissue, including both atrial and ventricular myocytes, where they can lead to triggered activity and tachyarrhythmias.…”
mentioning
confidence: 99%
See 1 more Smart Citation